schliessen

Filtern

 

Bibliotheken

1.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
by Reck, Martin

The New England journal of medicine, November 10, 2016, Vol.375(19), pp.1823-1833

3.

Pembrolizumab for the treatment of non-small-cell lung cancer.
by Garon, Edward B

The New England journal of medicine, May 21, 2015, Vol.372(21), pp.2018-2028

6.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
by Antonia, Scott J

The New England journal of medicine, November 16, 2017, Vol.377(20), pp.1919-1929

8.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
by Gandhi, Leena

The New England journal of medicine, May 31, 2018, Vol.378(22), pp.2078-2092

9.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
by Antonia, Scott J

The New England journal of medicine, December 13, 2018, Vol.379(24), pp.2342-2350

14.

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
by Fox, Peter

Clinical cancer research : an official journal of the American Association for Cancer Research, July 1, 2016, Vol.22(13), pp.3164-3171

Recommended databases

Find more Articles matching your search terms in these recommended databases.

Filter electronic articles 106 Hits

Cannot write session to /tmp/vufind_sessions/sess_sajab7cgj0kh5ouhppl45b7b67